市場調査レポート: 多形性膠芽腫（GBM）：パイプライン製品の分析

ホーム > 市場調査レポート > 医薬品 > パイプライン分析

	市場調査レポート多形性膠芽腫（GBM）：パイプライン製品の分析 Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2017
発行	Global Markets Direct			商品コード	229730
出版日	2017年12月13日	ページ情報	英文 1575 Pages
価格	USD 2,500 換算 276,075円 (税抜) PDF by E-mail (Single user license) レポートPDFを購入者の1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。 USD 5,000 換算 552,150円 (税抜) PDF by E-mail (Site license) レポートPDFについて、ご購入者が所属される同一事業所内の方で共有使用頂けます。同一事業所内であればご利用人数に制限はありません。PDF内のテキスト等のコピー＆ペースト可能です。PDF内コンテンツの印刷は制限なく何回でも可能ではありますが、全頁印刷版の作成利用は基本的には2部までとし、そのご利用はPDFのご利用範囲に準拠します。 USD 7,500 換算 828,225円 (税抜) PDF by E-mail (Global license) レポートPDFを同一企業の全世界の方にご使用頂けるライセンスです。ご利用人数に制限はありません。100％子会社は同一企業とみなされます。PDF内のテキスト等のコピー＆ペースト可能です。PDF内コンテンツの印刷は制限なく何回でも可能ではありますが、全頁印刷版の作成利用は基本的には10部までとし、そのご利用はPDFのご利用範囲に準拠します。本日の銀行送金レート: 1USD=110.43円で換算しております。

概要

多形性膠芽腫（GBM）は、最も一般的な悪性の原発性脳腫瘍です。GBMはダリア細胞（脳および脊髄内の神経細胞を保護する組織を形成する細胞）から生じます。GBMはアストロサイトとして知られる星状ダリア細胞（膠細胞）で構成されています。兆候と症状は、徐々に進行する神経障害、通常は運動麻痺、頭痛、頭蓋内圧亢進による全身症状（頭痛、悪心、嘔吐、認知障害、発作など）です。治療には、放射線療法、化学療法などが含まれます。

当レポートでは、多形性膠芽腫（GBM）に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

多形性膠芽腫（GBM）の概要

治療薬の開発

パイプライン製品：概要
パイプライン製品：比較分析

開発中の治療薬：企業別

調査中の治療薬：大学/研究機関別

パイプライン製品の概要

後期段階の製品
治験段階の製品
初期段階の製品
未確認段階の製品

開発中の製品：企業別

調査中の製品：大学/研究機関別

治療薬の開発に従事している企業

治療薬の評価

単独療法の場合
併用療法の場合
標的別
作用機序別
投与経路別
分子タイプ別

薬剤のプロファイル

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

最新ニュースとプレスリリース

付録

図表

Product Code: GMDHC10015IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2017, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.

Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 11, 106, 65, 1, 8, 155, 23 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 12, 14, 1, 36 and 11 molecules, respectively.

Glioblastoma Multiforme (GBM) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) (Oncology).
The pipeline guide reviews pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Glioblastoma Multiforme (GBM) (Oncology) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Glioblastoma Multiforme (GBM) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology).
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) (Oncology) pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Introduction
Glioblastoma Multiforme (GBM) - Overview
Glioblastoma Multiforme (GBM) - Therapeutics Development
Glioblastoma Multiforme (GBM) - Therapeutics Assessment
Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development
Glioblastoma Multiforme (GBM) - Drug Profiles
Glioblastoma Multiforme (GBM) - Dormant Projects
Glioblastoma Multiforme (GBM) - Discontinued Products
Glioblastoma Multiforme (GBM) - Product Development Milestones
Appendix

List of Tables

Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..9), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..10), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..11), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..12), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..13), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..14), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Products under Development by Companies, H2 2017 (Contd..6), H2 2017
Products under Development by Companies, H2 2017 (Contd..7), H2 2017
Products under Development by Companies, H2 2017 (Contd..8), H2 2017
Products under Development by Companies, H2 2017 (Contd..9), H2 2017
Products under Development by Companies, H2 2017 (Contd..10), H2 2017
Products under Development by Companies, H2 2017 (Contd..11), H2 2017
Products under Development by Companies, H2 2017 (Contd..12), H2 2017
Products under Development by Companies, H2 2017 (Contd..13), H2 2017
Products under Development by Companies, H2 2017 (Contd..14), H2 2017
Products under Development by Companies, H2 2017 (Contd..15), H2 2017
Products under Development by Companies, H2 2017 (Contd..16), H2 2017
Products under Development by Companies, H2 2017 (Contd..17), H2 2017
Products under Development by Companies, H2 2017 (Contd..18), H2 2017
Products under Development by Companies, H2 2017 (Contd..19), H2 2017
Products under Development by Companies, H2 2017 (Contd..20), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..7), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..8), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..9), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..7), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..8), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..9), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Number of Products by Stage and Molecule Type, H2 2017 (Contd..1), H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Accurexa Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Actuate Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Aduro BioTech Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Advantagene Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Advenchen Laboratories LLC, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Affimed GmbH, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Agenus Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Ambrx Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Amgen Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Ampio Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by AngioChem Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Apac Biotech Pvt Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by apceth Biopharma GmbH, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by APIM Therapeutics AS, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Apogenix AG, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Ariad Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Arog Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Astellas Pharma Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by AstraZeneca Plc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Athenex Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Basilea Pharmaceutica Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Batu Biologics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Bayer AG, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Beactica AB, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by BeiGene Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Berg LLC, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Bexion Pharmaceuticals LLC, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Bio-Path Holdings Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Bioasis Technologies Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by BioCancell Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Biovista Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Boston Biomedical Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Bristol-Myers Squibb Co, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Cantex Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Cavion LLC, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Celgene Corp, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Celldex Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Cellmid Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Celsion Corp, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by ChemoCentryx Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Coherus BioSciences Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Cortice Biosciences Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Critical Outcome Technologies Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Curtana Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Cynata Therapeutics Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by CytoVac AS, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Deciphera Pharmaceuticals LLC, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by DEKK-TEC Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by DelMar Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Diffusion Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Ecrins Therapeutics SAS, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Eisai Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Eli Lilly and Co, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by EnGeneIC Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Enterome Bioscience SA, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by EntreChem SL, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by ERC Belgium SA, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Erytech Pharma SA, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Evotec AG, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by F-star Biotechnology Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by FirstString Research Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Fujifilm Holdings Corporation, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Gene Techno Science Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Genentech Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Genisphere LLC, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Genor BioPharma Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by GlaxoSmithKline Plc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by GlioPharma ApS, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by GtreeBNT Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by GW Pharmaceuticals Plc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Hamlet Pharma AB, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Humanigen Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Hutchison MediPharma Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Immatics Biotechnologies GmbH, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Immune Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by ImmunoCellular Therapeutics Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Immunomedics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Immunomet Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Immunomic Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Incyte Corp, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Infinity Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Innovation Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Inovio Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Inspyr Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Insys Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Iovance Biotherapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Ipsen SA, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Janpix Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Johnson & Johnson, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Juno Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Kadmon Corp LLC, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Karyopharm Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Kazia Therapeutics Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Kite Pharma Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Komipharm International Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Kringle Pharma Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Les Laboratoires Servier SAS, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Lixte Biotechnology Holdings Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Loxo Oncology Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Mabion SA, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by MacroGenics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Medesis Pharma SA, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Medicenna Therapeutics Corp, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by MedImmune LLC, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Merck & Co Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Merck KGaA, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Midatech Pharma Plc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by MimiVax LLC, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Molecular Templates Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Moleculin Biotech Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Mycenax Biotech Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by NanoCarrier Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Nanomerics Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Nektar Therapeutics, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Neonc Technologies Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by NewLink Genetics Corp, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Northwest Biotherapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Novartis AG, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Noxopharm Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Noxxon Pharma AG, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Nuo Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by NuvOx Pharma LLC, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Omniox Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Oncobiologics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Oncodesign SA, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Onconova Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by OncoResponse Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Oncternal Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Orphit SAS, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Oryx GmbH & Co KG, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Ovensa Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Peloton Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Peptomyc SL, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Peregrine Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Pfizer Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Pharma Mar SA, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by PharmAbcine Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by PharmaCyte Biotech Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Pharmicell Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Phoenix Biotechnology Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by PIQUR Therapeutics AG, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Plex Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Plexxikon Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Prana Biotechnology Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by PTC Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Puma Biotechnology Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Regulus Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by ReNeuron Group Plc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Rgenix Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Richter Gedeon Nyrt, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Sanofi, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Sapience Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Scancell Holdings Plc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Sellas Life Sciences Group Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Sigma-Tau SpA, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by SignPath Pharma Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Silenseed Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by SOM Biotech SL, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Sorrento Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by StemGen SpA, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Stemline Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Sunesis Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Susavion Biosciences Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Symphogen A/S, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Synactix Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Systimmune Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Terpenoid Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Theralase Technologies Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Therapeia GmbH & Co KG, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Tocagen Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by TRACON Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Transgene SA, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Trillium Therapeutics Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by TVAX Biomedical Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Tyme Technologies Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Upsher-Smith Laboratories Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Vascular Biogenics Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Vault Pharma Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Vaximm AG, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by VBI Vaccines Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by VCN Biosciences SL, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by ViraTherapeutics GmbH, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Vyriad Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by X4 Pharmaceuticals Inc, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Xintela AB, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by Yooyoung Pharm Co Ltd, H2 2017
Glioblastoma Multiforme (GBM) - Pipeline by ZIOPHARM Oncology Inc, H2 2017
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd..1), H2 2017
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd..2), H2 2017
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd..3), H2 2017
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd..4), H2 2017
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd..5), H2 2017
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd..6), H2 2017
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd..7), H2 2017
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd..8), H2 2017
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd..9), H2 2017
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd..10), H2 2017
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2017 (Contd..11), H2 2017
Glioblastoma Multiforme (GBM) - Discontinued Products, H2 2017
Glioblastoma Multiforme (GBM) - Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures

Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

044-952-0102
(土日・祝日を除く)

よくあるご質問

メールサービス　キャンペーン

期間中に新規登録された方に
ご用意した無料レポートを提供中新規登録はこちら

ご利用のメリット

多形性膠芽腫（GBM）：パイプライン製品の分析 Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2017
出版日: 2017年12月13日	ページ情報: 英文 1575 Pages

多形性膠芽腫（GBM）：パイプライン製品の分析

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2017

目次